Rapport Therapeutics Inc (RAPP) Stock Price, Quote & News

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including periphe...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 321 8020

Website: www.rapportrx.com

Address:

1325 Boylston Street, Suite 401, Boston, United States

DonCorleone77 Jul. 1 at 10:58 AM

$RAPP Rapport Therapeutics files $400M mixed securities shelf

0 · Reply

bilocelhi Jun. 4 at 2:04 PM

$AGEN and $RAPP my top 2 bios

0 · Reply

QuiverQuant Jun. 2 at 8:07 PM

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline Read more on $RAPP: https://www.quiverquant.com/news/Rapport+Therapeutics+Hosts+Inaugural+Investor+and+Analyst+Day+to+Update+on+RAP-219+and+Clinical+Pipeline

0 · Reply

_www_larval_com_ Jun. 2 at 7:53 PM

$ZONE -22%[64%] $NIVF 4%[-12%] $KIDZ 3%[38%] $GPUS 3%[-12%] $RAPP 3%[15%] most notable movement into the final minutes of trading.

0 · Reply

lecorb May. 29 at 12:29 PM

$REVB $NTLA $RAPP Crashed

0 · Reply

mikedumbledar May. 29 at 11:59 AM

$RAPP why down 25%? i dont see any news

0 · Reply

JarvisFlow Apr. 8 at 4:45 PM

JMP Securities has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Market Outperform with a target price of 28.

0 · Reply

_www_larval_com_ Apr. 7 at 7:58 PM

$LHSW 6%[12%] $ARTV 4%[40%] $BJDX -3%[112%] $RAPP -3%[7%] most notable movement into the final minutes of trading.

0 · Reply

jParkz Apr. 5 at 9:01 PM

News out $RAPP (RAPP) Investment Analysis https://marketwirenews.com/news-releases/-rapp-investment-analysis-5446057280009633.html $RAPP

0 · Reply

Josephylor Apr. 4 at 7:46 PM

$RAPP In today's market downturn, savvy investors recognize that opportunities often arise when stocks are undervalued. Nuvve stands out as a compelling investment during these times. Competitive Edge: ✅ Advanced vehicle-to-grid (V2G) technology ✅ Bidirectional Charging: Unlike many competitors, Nuvve enables EVs to return power to the grid, enhancing grid efficiency ✅ AI-Powered Energy Management: Utilizes artificial intelligence to optimize energy flow and stabilize the grid ✅ Revenue Generation for EV Owners: Allows EV owners and fleet operators to earn by selling excess energy back to the grid

0 · Reply

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

May 27, 2025, 7:00 AM EDT - 5 weeks ago

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 6 weeks ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 8, 2025, 7:00 AM EDT - 2 months ago

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Apr 30, 2025, 11:45 AM EDT - 2 months ago

Mise à disposition du rapport financier annuel 2024

Apr 22, 2025, 7:00 AM EDT - 2 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Apr 18, 2025, 7:46 AM EDT - 2 months ago

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

Mar 21, 2025, 2:26 PM EDT - 3 months ago

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

Mar 21, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Mar 13, 2025, 12:14 PM EDT - 4 months ago

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 13, 2025, 3:00 AM EDT - 4 months ago

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 11, 2025, 7:00 AM EDT - 4 months ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:00 AM EST - 4 months ago

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Jan 9, 2025, 9:12 AM EST - 6 months ago

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Jan 9, 2025, 7:00 AM EST - 6 months ago

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Dec 6, 2024, 12:01 PM EST - 7 months ago

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Nov 14, 2024, 7:00 AM EST - 8 months ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Nov 4, 2024, 7:00 AM EST - 8 months ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 18, 2024, 10:51 AM EDT - 9 months ago

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

COFS NEON PCT SELF

Sep 17, 2024, 2:35 AM EDT - 10 months ago

Rapport semestriel Pilier 3 - 30 juin 2024

Sep 5, 2024, 7:00 AM EDT - 10 months ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Aug 29, 2024, 7:00 AM EDT - 11 months ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 7, 2024, 11:48 AM EDT - 1 year ago

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

JNJ

Jun 6, 2024, 7:57 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

JNJ

Jun 6, 2024, 6:54 PM EDT - 1 year ago

Rapport Therapeutics Announces Pricing of Initial Public Offering

Jun 3, 2024, 1:14 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

JNJ

May 22, 2024, 4:17 PM EDT - 1 year ago

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

DonCorleone77 Jul. 1 at 10:58 AM

$RAPP Rapport Therapeutics files $400M mixed securities shelf

0 · Reply

bilocelhi Jun. 4 at 2:04 PM

$AGEN and $RAPP my top 2 bios

0 · Reply

QuiverQuant Jun. 2 at 8:07 PM

0 · Reply

_www_larval_com_ Jun. 2 at 7:53 PM

$ZONE -22%[64%] $NIVF 4%[-12%] $KIDZ 3%[38%] $GPUS 3%[-12%] $RAPP 3%[15%] most notable movement into the final minutes of trading.

0 · Reply

lecorb May. 29 at 12:29 PM

$REVB $NTLA $RAPP Crashed

0 · Reply

mikedumbledar May. 29 at 11:59 AM

$RAPP why down 25%? i dont see any news

0 · Reply

JarvisFlow Apr. 8 at 4:45 PM

JMP Securities has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Market Outperform with a target price of 28.

0 · Reply

_www_larval_com_ Apr. 7 at 7:58 PM

$LHSW 6%[12%] $ARTV 4%[40%] $BJDX -3%[112%] $RAPP -3%[7%] most notable movement into the final minutes of trading.

0 · Reply

jParkz Apr. 5 at 9:01 PM

News out $RAPP (RAPP) Investment Analysis https://marketwirenews.com/news-releases/-rapp-investment-analysis-5446057280009633.html $RAPP

0 · Reply

Josephylor Apr. 4 at 7:46 PM

0 · Reply

Cutlass Mar. 27 at 7:31 PM

$RAPP Stay away - no pipeline, will need to do an offering too - 📉📋📣👀

0 · Reply

DonCorleone77 Mar. 11 at 11:14 AM

$RAPP Rapport Therapeutics sees cash runway through 2026 The Company ended the fourth quarter with $305.3 million in cash, cash equivalents and short-term investments, compared to $320.7 million as of September 30, 2024. The decrease was primarily due to cash outflows on operating activities in the fourth quarter of 2024. The Company expects that cash, cash equivalents, and short-term investments as of December 31, 2024 will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.

0 · Reply

DonCorleone77 Mar. 11 at 11:13 AM

$RAPP Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year "With continued execution in the fourth quarter, Rapport is well positioned to deliver on multiple meaningful development milestones. The RAP-219 Phase 2a trial in patients with refractory focal epilepsy continues to advance with strong momentum; patient enrollment and dosing are progressing as planned, and the trial remains on track to deliver topline results in the third quarter of 2025. Based on data from 100 healthy subjects dosed, we continue to have confidence in RAP-219's potential as a transformational medicine. The recently released PET and MAD-2 trial results demonstrated neuroanatomical specificity and favorable tolerability, further reinforcing our belief in its differentiated precision profile," said Abraham Ceesay, CEO. "We are committed to the pipeline-within-a-product strategy for RAP-219 and anticipate initiating a Phase 2a trial in bipolar mania in the third quarter of this year while continuing planning for our Phase 2a trial in diabetic peripheral neuropathic pain."

0 · Reply

_www_larval_com_ Mar. 6 at 8:52 PM

$RAPP 4%[-23%] $YOSH -4%[14%] $SCNX 4%[15%] most notable movement into the final minutes of trading.

0 · Reply

FurrrMom Mar. 5 at 12:37 AM

Giving credit where credit is due, I wouldn't have taken 37% profit on $RAPP if these guys hadn't called it when they did. No idea how they get ahead of these runners like they do. Had to be at least half-a-dozen today alone!

0 · Reply

IntraTrades Mar. 4 at 9:47 PM

$RAPP 50.68% $ATLN 40.12% $HOTH 36.11% $CLEU 35.98% $CTM 34.51%

0 · Reply

Aburose Mar. 4 at 7:56 PM

$RAPP Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of

0 · Reply

HaltTradeAlert Mar. 4 at 3:27 PM

$RAPP Halt Time: 10:24:45 Issue Symbol: RAPP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

0 · Reply

StocksPH Mar. 3 at 6:54 PM

$RAPP

0 · Reply

Cutlass Jan. 10 at 3:59 PM

$RAPP See......stay away.......will be years and many offerings to see the day light ✔📣📋

0 · Reply

DonCorleone77 Jan. 9 at 12:36 PM

$RAPP Rapport Therapeutics announces new Phase 1 data for RAP-219 Rapport Therapeutics announced results from its positron emission tomography trial and second multiple ascending dose trial for RAP-219. Data from the trials demonstrated that RAP-219 achieved target receptor occupancy associated with maximal efficacy in prior preclinical models within five days of dosing while maintaining a differentiated tolerability profile. "These Phase 1 results reinforce our belief in RAP-219's distinct profile and potential to deliver transformative outcomes for patients. The data demonstrate that neuroanatomical specificity can be achieved through RAP-219's selective targeting of a receptor-associated protein, and RAP-219 was able to quickly achieve target engagement and therapeutic exposures in the brain while maintaining a generally favorable tolerability profile. Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy," said Steve Paul, M.D., Rapport cofounder and chair of the board of directors.

0 · Reply

Quantumup Jan. 6 at 5:12 PM

TD Cowen: 10 POTENTIAL "THOME RUN" CATALYSTS TO WATCH IN 2025: ANAB, UTHR, QURE, ALKS, JAZZ, $PRME, $XENE, $PTCT, $RAPP, and $CMRX are highlighted: Mentioned: ITCI, VRDN MRNS, ANAB ADVM, AXSM THRD, ALLK: TD Cowen said: "We detail 10 expected 2025 catalysts from across our coverage universe, where we see the highest level of inbound interest, and potential stock movement implications. ANAB, UTHR, QURE, ALKS, JAZZ, PRME, XENE, PTCT, RAPP, and CMRX are highlighted:" - J. Thome

1 · Reply

Market Cap	439.44M
Revenue (ttm)	0.00
Net Income (ttm)	-78.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,800
Avg Vol	175,016
Day's Range	N/A - N/A
Shares Out	36.50M
Stochastic %K	74%
Beta	N/A
Analysts	Strong Sell
Price Target	$35.00